MedCap AB (FRA:61MA) Long-Term Debt: €14.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:61MA MedCap AB FRA:61MA
91 GF Score
Price €46.18
GF Value €50.15
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Long-Term Debt?

MedCap AB FRA:61MA -0.99% 91 Long-Term Debt is €14.8 Mil as of Jun. 2026. GuruFocus rates FRA:61MA with a GF Score™ of 91/100 and a GF Value™ of €50.15 (Fairly Valued).

MedCap AB's Long-Term Debt for the quarter that ended in Jun. 2026 was €14.8 Mil.

MedCap AB's quarterly Long-Term Debt increased from Dec. 2025 (€14.4 Mil) to Mar. 2026 (€16.1 Mil) but then declined from Mar. 2026 (€16.1 Mil) to Jun. 2026 (€14.8 Mil).

MedCap AB's annual Long-Term Debt declined from Dec. 2023 (€6.4 Mil) to Dec. 2024 (€4.2 Mil) but then increased from Dec. 2024 (€4.2 Mil) to Dec. 2025 (€14.4 Mil).

MedCap AB  (FRA:61MA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

MedCap AB Long-Term Debt Related Terms

MedCap AB Long-Term Debt Historical Data

* Premium members only.

The historical data trend for MedCap AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB Long-Term Debt Chart

MedCap AB Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.78 8.73 6.44 4.24 14.39

MedCap AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.32 17.92 14.39 16.11 14.79
FRA:61MA
91GF Score
MedCap AB FRA:61MA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €14.8 Mil mean?
MedCap AB (FRA:61MA) has a Long-Term Debt of €14.8 Mil as of Jun. 2026.
Is MedCap AB's Long-Term Debt too high?
MedCap AB's current Long-Term Debt is €14.8 Mil. Overall, MedCap AB has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Long-Term Debt compare to ABT and SYK?
MedCap AB's Long-Term Debt of €14.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. MedCap AB's current Long-Term Debt is €14.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (FRA:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €50.15, compared to a current price of €46.18 — trading 7.9% below its estimated fair value. The current Long-Term Debt is €14.8 Mil. MedCap AB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For MedCap AB (FRA:61MA), the current Long-Term Debt is €14.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (FRA:61MA) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of €46.18 is trading 7.9% below its estimated GF Value™ of €50.15. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for FRA:61MA:

  • Long-Term Debt: €14.8 Mil
  • GF Value™: €50.15 vs. price of €46.18 (7.9% below fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the FRA:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedCap AB Business Description

Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
91GF Score

Get the complete analysis for FRA:61MA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€50.15
GF Value